Drug trial offers hope for Tough-to-Treat blood disorder
NCT ID NCT03988608
Summary
This study tested whether the drug eltrombopag could help Chinese adults with severe aplastic anemia, a serious blood disorder, when other treatments had failed. Twenty participants took the drug daily for up to a year, with doctors checking if their blood cell counts improved. The goal was to see if the drug could reduce the need for blood transfusions and control the disease.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for APLASTIC ANEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Novartis Investigative Site
Nanjing, Jiangsu, 210000, China
-
Novartis Investigative Site
Nanchang, Jiangxi, 330006, China
-
Novartis Investigative Site
Chengdu, Sichuan, 610041, China
-
Novartis Investigative Site
Tianjin, 300020, China
-
Novartis Investigative Site
Tianjin, 300052, China
Conditions
Explore the condition pages connected to this study.